Skip to main content

Table 1 Baseline characteristics, preoperative clinical and laboratory data and histopathological characteristics of patients with pancreatic ductal adenocarcinoma (PDAC) (n = 236)

From: Pancreatic fibrosis, acinar atrophy and chronic inflammation in surgical specimens associated with survival in patients with resectable pancreatic ductal adenocarcinoma

 

n = 236

Age at the time of surgery (in years)

67.5 (39.2–85.9)

Sex, male / female

123 (52.1%) / 113 (47.9%)

ASA class

  I–II

110 (46.6%)

  III–IV

126 (53.4%)

BMI (kg/m2) (n = 210)

25.3 (15.8–40.1)

Tobacco smoking (n = 227)

  Never smoker

115 (48.7%)

  Current smoker

46 (19.5%)

  Former smoker

58 (24.6%)

Alcohol consumption (n = 231)

 Ongoing alcohol misuse

20 (8.5%)

 Heavy alcohol intake (ever)

28 (11.9%)

History of diabetes mellitus

  No

174 (73.7%)

  Yes

62 (26.3%)

  Duration of diabetes, in months (n = 34)

12.0 (1.0–336.0)

Blood type

  A

117 (49.6%)

  B

40 (16.9%)

  AB

27 (11.4%)

  O

52 (22.0%)

Symptoms

  Jaundice (n = 235)

184 (78.0%)

  Abdominal or back pain (n = 235)

105 (44.5%)

  Weight loss (n = 234)

96 (40.7%)

  Steatorrhea (n = 234)

26 (11.0%)

Preoperative imaging

  CT

232 (98.3%)

  MRCP

67 (28.4%)

  Upper abdominal MRI

61 (25.8%)

  US

199 (84.3%)

  EUS

29 (12.3%)

  EUS-FNA

18 (7.6%)

  FDG-PET-CT

5 (2.1)

Preoperative blood test

  CRP (mg/l) (n = 149)

5.0 (1.0–124.0)

  High-sensitivity CRP (mg/l) (n = 186)

3.4 (0.06–135.5)

  Total bilirubin (μmol/l)

17.0 (4.0–511.0)

  Ca 19–9 (kU/l) (n = 231)

139.0 (1.0–35,770.0)

  CEA (μg/l) (n = 229)

2.7 (1.0–68.9)

  Albumin (g/l) (n = 234)

36.5 (22.6–46.5)

Location of pancreatic cancer

  Head of the pancreas

232 (99.2%)

  Body of the pancreas

2 (0.8%)

T status (n = 235)

  T1

25 (10.6%)

  T2

164 (69.5%)

  T3

37 (15.7%)

  T4

9 (3.8%)

LN metastasis (n = 234)

  N0

62 (26.3%)

  N1

171 (72.5%)

  N2

1 (0.4%)

Tumor size (mm) (n = 232)

  ≤30 mm

123 (52.1%)

  > 30 mm

109 (46.2%)

Perivascular invasion (n = 201)

77 (32.6%)

Perineural invasion (n = 216)

174 (73.7%)

R status (n = 231)

  R0

178 (75.4%)

  R1

55 (22.5%)

Adjuvant chemotherapy

147 (62.3%)

  1. Figures consist of the number of patients (%) or median (range)
  2. Abbreviations: ASA American Society of Anesthesiologists; BMI body mass index; CT computed tomography; DM diabetes mellitus; EUS endoscopic ultrasound; EUS-FNA endoscopic ultrasound-guided fine needle aspiration biopsy; FDG-PET-CT fluorodeoxyglucose (FDG) positron emission tomography (PET); MRCP magnetic resonance cholangiopancreatography; MRI magnetic resonance imaging; US ultrasound